Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

CAO Junqiu ,  LI Bo

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

LI Bo, Email: cdhxlb@126.com

Keywords：

recurrent hepatocellular carcinoma; treatment; comparison of therapeutic effect

DOI：

10.7507/1007-9424.202008063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the current comparison of the efficacy of different treatments for recurrent hepatocellular carcinoma.Method To search the literatures about the comparative studies on the efficacy of different treatments for recurrent hepatocellular carcinoma in recent years and analyze them.Results In the treatment of recurrent hepatocellular carcinoma, percutaneous arterial chemoembolization combined with radiofrequency ablation could improve the survival rate and tumor-free survival rate to some extent, compared with the single use of percutaneous arterial chemoembolization. In the short term, there was no difference in efficacy between radiofrequency ablation and surgical resection, but the local recurrence rate of radiofrequency ablation was higher than that of surgical resection group. Salvage liver transplantation offered potential opportunity to reduce the risk of recurrence and tended to improve long-term survival outcomes, but liver sources were scarce and costly. Conclusions At present, there is no systematic staging scheme and treatment system for recurrent hepatocellular carcinoma. At the same time, most studies are retrospective, and more prospective studies are needed to further explore the treatment of recurrent hepatocellular carcinoma.

Citation： CAO Junqiu, LI Bo. Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(5): 695-698. doi: 10.7507/1007-9424.202008063 Copy

1.	Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127): 1301-1314.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	丛文铭, 吴孟超. 肝癌术后复发的发生机制及临床病理学意义. 中国实用外科杂志, 2012, 32(10): 809-811.
4.	Saraswat VA, Pandey G, Shetty S. Treatment algorithms for man aging hepatocellular carcinoma. J Clin Exp Hepatol, 2014, 4(Suppl 3): 80-89.
5.	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019 年版). 中国实用外科杂志, 2020, 40(2): 121-138.
6.	Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480.
7.	Famularo S, Di Sandro S, Giani A, et al. Recurrence patterns after anatomic or parenchyma-sparing liver resection for hepatocellular carcinoma in a western population of cirrhotic patients. Ann Surg Oncol, 2018, 25(13): 3974-3981.
8.	Xiao H, Chen ZB, Jin HL, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res, 2019, 11(3): 1864-1875.
9.	Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
10.	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822): 1245-1255.
11.	Choo SP, Tan WL, Goh BKP, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer, 2016, 122(22): 3430-3446.
12.	Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol, 2014, 20(39): 14505-14509.
13.	毛廷辉, 吴刚. 复发性肝癌靶向治疗及免疫治疗. 中国实用外科杂志, 2019, 39(10): 1048-1051.
14.	张耀军, 陈敏山. 肝癌术后复发的多学科综合治疗. 中国实用外科杂志, 2019, 39(10): 1042-1044.
15.	Tham S, Cai M, Syn N, et al. Utility of TACE and RFA for unresectable recurrent HCC: inverse probability of treatment-weighted subgroup analyses of overall survival. HPB, 2019, 21(Supl 2): S240.
16.	Wang X, Liang H, Lu Z. Efficacy of transarterial chemo-embolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol, 2020, 29(6): 344-352.
17.	Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/A: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836.
18.	Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78.
19.	莫嘉强, 何军明, 刁竞芳, 等. 超声微创介入治疗复发性肝癌的临床疗效及预后分析. 中国数字医学, 2020, 15(4): 96-98.
20.	Wang C, Liao Y, Qiu J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680.
21.	舒强, 刘小玲, 杨小李, 等. 经导管肝动脉化疗栓塞术联合经皮微波消融治疗复发性肝癌的预后分析. 中国普通外科杂志, 2020, 29(1): 11-18.
22.	Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol, 2020, 6(2): 255-263.
23.	Feng Y, Wu H, Huang DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤5 cm) after initial curative resection. Eur Radiol, 2020, 30(11): 6357-6368.
24.	刘嘉龙, 黄登, 曹利, 等. 腹腔镜肝切除术和射频消融术治疗复发性肝癌的前瞻性随机对照研究(中期随访分析). 第三军医大学学报, 2019, 41(5): 467-472.
25.	谭增光, 冯树开, 王军, 等. 复发性小肝癌采用经皮肝穿刺射频消融与再次肝切除的疗效比较. 医学理论与实践, 2020, 33(11): 1790-1792.
26.	李春丽, 董巧云, 侯丽, 等. 二次切除手术与经皮射频消融治疗切除后复发性肝细胞肝癌的临床疗效和预后分析. 中国医学装备, 2019, 16(12): 47-51.
27.	张波涛, 崔智飞, 段希斌, 等. 射频消融术和腹腔镜肝切除术治疗复发性肝癌的临床疗效及远期生存情况分析. 癌症进展, 2020, 18(5): 482-484, 499.
28.	陈康, 刘新宇, 滕煜宪, 等. 再次肝切除与射频消融治疗复发性肝癌疗效对比研究. 中国实用外科杂志, 2019, 39(10): 1060-1064.
29.	Midorikawa Y, Takayama T, Moriguchi M, et al. Liver resection versus embolization for recurrent hepatocellular carcinoma. World J Surg, 2020, 44(1): 232-240.
30.	Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419.
31.	Hu Z, Zhou J, Xu X. et al Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One, 2012, 7(5): e36587.
32.	Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl, 2017, 23(12): 1553-1563.
33.	Ma KW, Chok KSH, She WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: A propensity score matched analysis. Liver Transpl, 2018, 24(8): 1062-1069.
34.	Guo Y, Tan EK, Syn NL, et al. Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 305-312.
35.	Fang JZ, Xiang L, Hu YK, et al. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant, 2020, 34(5): e13831.
36.	高本见, 罗佳, 刘莹, 等. 挽救性肝移植与再次肝切除治疗术后复发性肝癌疗效对比的 Meta 分析. 中国普通外科杂志, 2020, 29(1): 1-10.
37.	Hanyong S, Wanyee L, Siyuan F, et al. A prospective randomized controlled trial: comparison of two different methods of hepatectomy. Eur J Surg Oncol, 2015, 41(2): 243-248.
38.	Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25.
39.	Onoe T, Yamaguchi M, Irei T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc, 2020, 34(10): 4574-4581.
40.	Cai W, Liu Z, Xiao Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc, 2019, 33(11): 3550-3557.
41.	Gon H, Kido M, Tanaka M, et al. Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surg Endosc, 2020. Online ahead of print.

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127): 1301-1314.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. 丛文铭, 吴孟超. 肝癌术后复发的发生机制及临床病理学意义. 中国实用外科杂志, 2012, 32(10): 809-811.
4. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for man aging hepatocellular carcinoma. J Clin Exp Hepatol, 2014, 4(Suppl 3): 80-89.
5. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019 年版). 中国实用外科杂志, 2020, 40(2): 121-138.
6. Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480.
7. Famularo S, Di Sandro S, Giani A, et al. Recurrence patterns after anatomic or parenchyma-sparing liver resection for hepatocellular carcinoma in a western population of cirrhotic patients. Ann Surg Oncol, 2018, 25(13): 3974-3981.
8. Xiao H, Chen ZB, Jin HL, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res, 2019, 11(3): 1864-1875.
9. Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
10. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822): 1245-1255.
11. Choo SP, Tan WL, Goh BKP, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer, 2016, 122(22): 3430-3446.
12. Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol, 2014, 20(39): 14505-14509.
13. 毛廷辉, 吴刚. 复发性肝癌靶向治疗及免疫治疗. 中国实用外科杂志, 2019, 39(10): 1048-1051.
14. 张耀军, 陈敏山. 肝癌术后复发的多学科综合治疗. 中国实用外科杂志, 2019, 39(10): 1042-1044.
15. Tham S, Cai M, Syn N, et al. Utility of TACE and RFA for unresectable recurrent HCC: inverse probability of treatment-weighted subgroup analyses of overall survival. HPB, 2019, 21(Supl 2): S240.
16. Wang X, Liang H, Lu Z. Efficacy of transarterial chemo-embolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol, 2020, 29(6): 344-352.
17. Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/A: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836.
18. Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78.
19. 莫嘉强, 何军明, 刁竞芳, 等. 超声微创介入治疗复发性肝癌的临床疗效及预后分析. 中国数字医学, 2020, 15(4): 96-98.
20. Wang C, Liao Y, Qiu J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680.
21. 舒强, 刘小玲, 杨小李, 等. 经导管肝动脉化疗栓塞术联合经皮微波消融治疗复发性肝癌的预后分析. 中国普通外科杂志, 2020, 29(1): 11-18.
22. Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol, 2020, 6(2): 255-263.
23. Feng Y, Wu H, Huang DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤5 cm) after initial curative resection. Eur Radiol, 2020, 30(11): 6357-6368.
24. 刘嘉龙, 黄登, 曹利, 等. 腹腔镜肝切除术和射频消融术治疗复发性肝癌的前瞻性随机对照研究(中期随访分析). 第三军医大学学报, 2019, 41(5): 467-472.
25. 谭增光, 冯树开, 王军, 等. 复发性小肝癌采用经皮肝穿刺射频消融与再次肝切除的疗效比较. 医学理论与实践, 2020, 33(11): 1790-1792.
26. 李春丽, 董巧云, 侯丽, 等. 二次切除手术与经皮射频消融治疗切除后复发性肝细胞肝癌的临床疗效和预后分析. 中国医学装备, 2019, 16(12): 47-51.
27. 张波涛, 崔智飞, 段希斌, 等. 射频消融术和腹腔镜肝切除术治疗复发性肝癌的临床疗效及远期生存情况分析. 癌症进展, 2020, 18(5): 482-484, 499.
28. 陈康, 刘新宇, 滕煜宪, 等. 再次肝切除与射频消融治疗复发性肝癌疗效对比研究. 中国实用外科杂志, 2019, 39(10): 1060-1064.
29. Midorikawa Y, Takayama T, Moriguchi M, et al. Liver resection versus embolization for recurrent hepatocellular carcinoma. World J Surg, 2020, 44(1): 232-240.
30. Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419.
31. Hu Z, Zhou J, Xu X. et al Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One, 2012, 7(5): e36587.
32. Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl, 2017, 23(12): 1553-1563.
33. Ma KW, Chok KSH, She WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: A propensity score matched analysis. Liver Transpl, 2018, 24(8): 1062-1069.
34. Guo Y, Tan EK, Syn NL, et al. Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 305-312.
35. Fang JZ, Xiang L, Hu YK, et al. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant, 2020, 34(5): e13831.
36. 高本见, 罗佳, 刘莹, 等. 挽救性肝移植与再次肝切除治疗术后复发性肝癌疗效对比的 Meta 分析. 中国普通外科杂志, 2020, 29(1): 1-10.
37. Hanyong S, Wanyee L, Siyuan F, et al. A prospective randomized controlled trial: comparison of two different methods of hepatectomy. Eur J Surg Oncol, 2015, 41(2): 243-248.
38. Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25.
39. Onoe T, Yamaguchi M, Irei T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc, 2020, 34(10): 4574-4581.
40. Cai W, Liu Z, Xiao Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc, 2019, 33(11): 3550-3557.
41. Gon H, Kido M, Tanaka M, et al. Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surg Endosc, 2020. Online ahead of print.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content